SRT-1720

SRT-1720 is a drug developed by Sirtris Pharmaceuticals, which is a subsidiary of GlaxoSmithKline. It is a synthetic compound designed to mimic the beneficial health effects of resveratrol, a naturally occurring molecule found in red wine, which is believed to activate sirtuins, a class of proteins that are thought to play a role in aging.

Mechanism of Action

SRT-1720 is designed to bind to and activate SIRT1, a specific sirtuin that is believed to regulate certain metabolic processes, including the release of insulin, the breakdown of glucose, and the function of mitochondria, the energy-producing structures within cells. By activating SIRT1, SRT-1720 is thought to improve metabolic function and potentially extend lifespan, although this has not been definitively proven in humans.

Research and Development

SRT-1720 was first synthesized in 2007 as part of a research program aimed at developing drugs that could mimic the effects of a calorie-restricted diet, which has been shown to extend lifespan in a variety of organisms. Early studies in mice suggested that SRT-1720 could improve insulin sensitivity, reduce cholesterol levels, and extend lifespan, although these findings have been controversial.

In 2010, a study published in the journal Nature reported that SRT-1720 could protect mice against diet-induced obesity and insulin resistance, suggesting potential applications in the treatment of type 2 diabetes and metabolic syndrome. However, subsequent studies have yielded mixed results, and the drug is not currently approved for use in humans.

Safety and Efficacy

The safety and efficacy of SRT-1720 are still under investigation. While early studies in mice suggested potential benefits, subsequent research has yielded mixed results. Some studies have reported potential side effects, including liver toxicity, while others have found no significant adverse effects. Further research is needed to fully understand the safety and efficacy of SRT-1720 in humans.

See Also

• Resveratrol
• Sirtuins
• Sirtris Pharmaceuticals
• GlaxoSmithKline
• SIRT1
• Type 2 diabetes
• Metabolic syndrome